R&D channel feed

In glimpse of tiny pa­tient group, IN8bio’s ‘off-the-shelf’ gam­ma delta T cells re­main durable

3 years ago

Hal Bar­ron’s swan song at GSK: An ‘ex­cep­tion­al’ lega­cy, thoughts on risk and a sin­gu­lar de­ci­sion-mak­ing mod­el

3 years ago

RNAi for com­mon dis­eases? Al­ny­lam plans to forge a path for­ward, start­ing with new obe­si­ty gene tar­get

3 years ago
Discovery

Ob­sE­va im­plodes on warn­ing that the FDA has set up a road­block for its flag­ship drug

3 years ago

In an­oth­er ac­cel­er­at­ed ap­proval quest, Bio­gen will send its ALS drug to the FDA de­spite in­con­clu­sive da­ta

3 years ago
FDA+

As Mer­ck buy­out buzz heats up, Seagen touts a pos­i­tive up­date on their Pad­cev/Keytru­da com­bo

3 years ago

J&J looks to ex­pand Ry­bre­vant lung can­cer in­di­ca­tion to larg­er EGFR-pos­i­tive pop­u­la­tion

3 years ago

'Go quick­ly': Am­gen R&D vet Dirk Nagors­en jumps to a start­up with big plans for TCRs

3 years ago
People

Tar­get­ing Bio­Mar­in's new drug fran­chise, Bridge­Bio CEO Neil Ku­mar cel­e­brates an in­ter­im win. But is it good enough?

3 years ago

Fol­low­ing a host of tri­al flops, An­gion halts R&D work, search­es for ‘strate­gic al­ter­na­tives’

3 years ago

Take­da is head­ing to the FDA with pos­i­tive PhI­II re­sults for HyQvia in rare au­toim­mune dis­ease

3 years ago

Four months af­ter first in­tranasal flunks in­fluen­za test, Rev­e­la­tion's sec­ond-gen as­set miss­es on ef­fi­ca­cy

3 years ago

Bavar­i­an Nordic nabs EU ap­proval for mon­key­pox vac­cine as WHO de­clares glob­al health emer­gency

3 years ago
Pharma

On a roll, As­traZeneca flags loom­ing ap­provals for three big drug fran­chis­es

3 years ago
FDA+

J&J's BC­MA/CD3 bis­pe­cif­ic nabs a con­di­tion­al EMA nod, jump­ing in front of FDA

3 years ago

Vista­Gen faces an­oth­er fail as anx­i­ety drug flops a PhI­II study — shares crater

3 years ago

'Like a bul­let­proof vest': Can­cer cells make their own kind of col­la­gen. Can pierc­ing through make treat­ments bet­ter?

3 years ago
Discovery

Small UK biotech touts long-term da­ta for he­mo­phil­ia B gene ther­a­py as it at­tempts a come­back

3 years ago
Cell/Gene Tx

Roche trims out some pipeline fail­ures while flag­ging a PhI­II flop for Tecen­triq

3 years ago

Pfiz­er to make ma­jor in­vest­ment in vac­cine R&D and man­u­fac­tur­ing site in New York

3 years ago
Manufacturing

X4 slash­es pipeline, lays off staff just three weeks af­ter net­ting a $55M PIPE

3 years ago
People

John McHutchi­son throws in the tow­el on HBV drug, trig­ger­ing lay­offs as As­sem­bly shifts to next-gen ap­proach­es

3 years ago
People

Mi­cro­cap biotech's shares crater on a PhI­II fail­ure for heavy drink­ing drug

3 years ago

With­out vol­un­tary with­drawals, ODAC to re­view two more dan­gling ac­cel­er­at­ed ap­provals

3 years ago
FDA+
First page Previous page 126127128129130131132 Next page Last page
A service from the Financial Times